Page last updated: 2024-11-02

pioglitazone and Dyslipidemias

pioglitazone has been researched along with Dyslipidemias in 43 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.

Research Excerpts

ExcerptRelevanceReference
" After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10."9.24Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia. ( Akhtar, L; Hussain, M; Shad, MN, 2017)
" A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days."9.19Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. ( Kawamori, R; Kitagawa, K; Kitakaze, M; Matsuhisa, M; Matsumoto, M; Onuma, T; Watada, H; Yamasaki, Y; Yamazaki, T; Yoshii, H, 2014)
" We studied the effects of pioglitazone (PIO) and rosiglitazone (ROSI) treatments on serum lipoprotein particle concentrations and sizes in type 2 diabetic patients with dyslipidemia."9.12Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. ( Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Tan, MH; Zagar, AJ, 2007)
"The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats."7.91Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019)
" Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits."7.77Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011)
" Baseline parameters came from a multi-center, double-blind trial comparing lipid and glycemic effects of pioglitazone (n = 400) and rosiglitazone (n = 402) among individuals with T2DM and untreated dyslipidemia."7.74Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. ( Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL, 2008)
" The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha."7.73The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006)
"Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles."6.76PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011)
"Treatment with pioglitazone, BCP, BCP + CB2R antagonist, AM630, or BCP + PPAR-γ antagonist, BADGE was started from the 9th week and continued till the 12th week."5.51Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors. ( El-Fayoumi, HM; Mahmoud, MF; Youssef, DA, 2019)
"Biochemical markers of NAFLD worsened over time."5.40Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014)
" After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10."5.24Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia. ( Akhtar, L; Hussain, M; Shad, MN, 2017)
"Fenofibrate is a peroxisome proliferator-activated receptor-α that has been clinically used to treat dyslipidemia and insulin resistance."5.19Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue. ( Chen, M; Deng, D; Fang, Z; Hu, H; Luo, L; Wang, Y; Xu, M, 2014)
" A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days."5.19Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. ( Kawamori, R; Kitagawa, K; Kitakaze, M; Matsuhisa, M; Matsumoto, M; Onuma, T; Watada, H; Yamasaki, Y; Yamazaki, T; Yoshii, H, 2014)
" In this study, we administered pioglitazone and pitavastatin for 16 weeks to 18 patients who had type 2 diabetes complicated by dyslipidemia and then investigated the influence of these 2 drugs on MDA-LDL(i."5.15[Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes]. ( Hayashi, S; Taguchi, A, 2011)
"Three-month treatment with pioglitazone improved glycaemic control, homeostasis model assessment for insulin resistance (HOMA), dyslipidaemia and liver function tests in association with a marked increase in serum HMW adiponectin level."5.14Withdrawal of pioglitazone in patients with type 2 diabetes mellitus. ( Asano, T; Hiramatsu, S; Iida, M; Iwase, M; Ogo, A; Sakai, Y; Sasaki, N; Yoshizumi, H, 2010)
" We studied the effects of pioglitazone (PIO) and rosiglitazone (ROSI) treatments on serum lipoprotein particle concentrations and sizes in type 2 diabetic patients with dyslipidemia."5.12Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. ( Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Tan, MH; Zagar, AJ, 2007)
" This study compared the efficacy of tesaglitazar with that of pioglitazone as adjunctive therapy to atorvastatin in subjects with abdominal obesity and dyslipidemia."5.12The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. ( Lindberg, MB; Ohman, KP; Ose, L; Retterstøl, K; Svensson, M; Tonstad, S, 2007)
"This paper reviewed the effects of pioglitazone and rosiglitazone on atherogenic diabetic dyslipidemia, in particular on small dense low-density lipoprotein particles."4.84The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance? ( Berneis, K; Christ, ER; Rini, GB; Rizzo, M; Spinas, GA, 2008)
"Pioglitazone is an antihyperglycaemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake."4.83Pioglitazone: a review of its use in type 2 diabetes mellitus. ( Easthope, S; Keating, GM; Plosker, GL; Robinson, DM; Waugh, J, 2006)
" Pioglitazone, an antidiabetic agent that acts primarily by decreasing insulin resistance, improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis."4.82The metabolic basis of atherogenic dyslipidemia. ( Vinik, AI, 2005)
"The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats."3.91Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019)
" Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits."3.77Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011)
" Baseline parameters came from a multi-center, double-blind trial comparing lipid and glycemic effects of pioglitazone (n = 400) and rosiglitazone (n = 402) among individuals with T2DM and untreated dyslipidemia."3.74Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. ( Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL, 2008)
" The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha."3.73The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006)
"Statin therapy is safe in patients with prediabetes/T2DM and NASH."2.84Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. ( Bril, F; Cusi, K; Hecht, J; Lomonaco, R; Orsak, B; Portillo Sanchez, P; Tio, F, 2017)
"Type 2 diabetes is a major risk factor for chronic kidney disease, which substantially increases the risk of cardiovascular disease mortality."2.79Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. ( Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D, 2014)
"Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles."2.76PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011)
"Though gout is more prevalent in men than women, it remains unclear whether gender influences risk factors for incident gout."2.61Gender-specific risk factors for gout: a systematic review of cohort studies. ( Belcher, J; Evans, PL; Hay, CA; Mallen, CD; Prior, JA; Roddy, E, 2019)
"Statins have a primary role in the treatment of dyslipidemia in people with type 2 diabetes, defined as triglyceride levels >200 mg/dl and HDL cholesterol levels <40 mg/dL."2.55Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. ( Anabtawi, A; Miles, JM; Moriarty, PM, 2017)
"Nonalcoholic fatty liver disease is the most common cause of liver dysfunction in the western world because of its close association with obesity, insulin resistance and dyslipidaemia."2.52Nonalcoholic fatty liver disease: new treatments. ( Anstee, QM; Day, CP; Hardy, T, 2015)
"Treatment with Rosiglitazone should be reconsidered because of a potential cardiovascular risk."2.44[Therapy with glitazones--a risk for cardiovascular disease?]. ( Erdmann, E; Hoppe, UC; Michels, G; Rottlaender, D, 2007)
"Treatment with pioglitazone, BCP, BCP + CB2R antagonist, AM630, or BCP + PPAR-γ antagonist, BADGE was started from the 9th week and continued till the 12th week."1.51Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors. ( El-Fayoumi, HM; Mahmoud, MF; Youssef, DA, 2019)
"Biochemical markers of NAFLD worsened over time."1.40Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014)
"Pioglitazone has been shown to significantly reduce cardiovascular adverse outcomes, while preliminary data on IBTs are very encouraging as well."1.39Non-glycemic effects of pioglitazone and incretin-based therapies. ( Avogaro, A; Montalto, G; Rizvi, AA; Rizzo, M, 2013)
"Fenofibrate treatment significantly improved lipoprotein metabolism toward a less atherogenic phenotype but did not affect insulin sensitivity."1.33PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. ( Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G, 2005)

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's18 (41.86)29.6817
2010's23 (53.49)24.3611
2020's2 (4.65)2.80

Authors

AuthorsStudies
Liu, W1
Liu, K1
Wood, HB1
McCann, ME1
Doebber, TW1
Chang, CH1
Akiyama, TE1
Einstein, M1
Berger, JP1
Meinke, PT1
Aggarwal, H1
Pathak, P1
Kumar, Y1
Jagavelu, K1
Dikshit, M1
Krishnappa, M1
Patil, K1
Parmar, K1
Trivedi, P1
Mody, N1
Shah, C1
Faldu, K1
Maroo, S1
Parmar, D1
Yamada, T1
Hiraoka, E1
Miyazaki, T1
Sato, J1
Ban, N1
Anabtawi, A1
Moriarty, PM1
Miles, JM1
Bril, F1
Portillo Sanchez, P1
Lomonaco, R1
Orsak, B1
Hecht, J1
Tio, F1
Cusi, K1
Hussain, M1
Shad, MN1
Akhtar, L1
Hirano, T1
Youssef, DA1
El-Fayoumi, HM1
Mahmoud, MF1
Shawky, NM1
Shehatou, GSG1
Suddek, GM1
Gameil, NM1
Corey, KE1
Wilson, LA1
Altinbas, A1
Yates, KP1
Kleiner, DE1
Chung, RT1
Krauss, RM1
Chalasani, N2
Evans, PL1
Prior, JA1
Belcher, J1
Hay, CA1
Mallen, CD1
Roddy, E1
Rizzo, M2
Avogaro, A1
Montalto, G1
Rizvi, AA1
Chen, M1
Deng, D1
Fang, Z1
Xu, M1
Hu, H1
Luo, L1
Wang, Y1
Riche, DM1
Fleming, JW1
Malinowski, SS1
Black, CA1
Miller, KH1
Wofford, MR1
Yoshii, H1
Onuma, T1
Yamazaki, T1
Watada, H1
Matsuhisa, M1
Matsumoto, M1
Kitagawa, K1
Kitakaze, M1
Yamasaki, Y1
Kawamori, R1
Ibáñez, L1
Ong, KK1
López-Bermejo, A1
Dunger, DB1
de Zegher, F1
Perségol, L1
Duvillard, L1
Monier, S1
Brindisi, MC1
Bouillet, B1
Petit, JM1
Vergès, B2
Ruilope, L1
Hanefeld, M1
Lincoff, AM1
Viberti, G1
Meyer-Reigner, S1
Mudie, N1
Wieczorek Kirk, D1
Malmberg, K1
Herz, M1
Hardy, T1
Anstee, QM1
Day, CP1
Liu, HJ1
Zhang, CY1
Song, F1
Xiao, T1
Meng, J1
Zhang, Q1
Liang, CL1
Li, S1
Wang, J2
Zhang, B1
Liu, YR1
Sun, T1
Zhou, HG1
Derosa, G1
Salvadeo, SA1
Christ, ER1
Rini, GB1
Spinas, GA1
Berneis, K1
Tunis, SL1
Minshall, ME1
St Charles, M1
Pandya, BJ1
Baran, RW1
Vuppalanchi, R1
Iwase, M1
Asano, T1
Sasaki, N1
Yoshizumi, H1
Hiramatsu, S1
Sakai, Y1
Ogo, A1
Iida, M1
Taguchi, A1
Hayashi, S1
Pfützner, A1
Schöndorf, T1
Tschöpe, D2
Lobmann, R1
Merke, J1
Müller, J1
Lehmann, U1
Fuchs, W1
Forst, T2
Zhang, X1
Zhang, R1
Raab, S1
Zheng, W1
Liu, N1
Zhu, T1
Xue, L1
Song, Z1
Mao, J1
Li, K1
Zhang, H1
Zhang, Y1
Han, C1
Ding, Y1
Wang, H1
Hou, N1
Liu, Y1
Shang, S1
Li, C1
Sebokova, E1
Cheng, H1
Huang, PL1
Shinohara, Y1
Hennuyer, N1
Tailleux, A1
Torpier, G1
Mezdour, H1
Fruchart, JC1
Staels, B1
Fiévet, C1
Betteridge, DJ1
Waugh, J1
Keating, GM1
Plosker, GL1
Easthope, S1
Robinson, DM1
Vinik, AI1
Trogan, E1
Feig, JE1
Dogan, S1
Rothblat, GH1
Angeli, V1
Tacke, F1
Randolph, GJ1
Fisher, EA1
Li, PP1
Shan, S1
Chen, YT1
Ning, ZQ1
Sun, SJ1
Liu, Q1
Lu, XP1
Xie, MZ1
Shen, ZF1
Berhanu, P1
Kipnes, MS1
Khan, MA2
Perez, AT2
Kupfer, SF1
Spanheimer, RC1
Demissie, S1
Fleck, PR1
Yoshiuchi, I1
Itoh, N1
Nakano, M1
Tatsumi, C1
Yokoyama, K1
Matsuyama, T1
Deeg, MA1
Buse, JB1
Goldberg, RB1
Kendall, DM1
Zagar, AJ1
Jacober, SJ1
Tan, MH1
Tonstad, S1
Retterstøl, K1
Ose, L1
Ohman, KP1
Lindberg, MB1
Svensson, M1
Comaschi, M1
Corsi, A1
Di Pietro, C1
Bellatreccia, A1
Mariz, S1
Rottlaender, D1
Michels, G1
Erdmann, E2
Hoppe, UC1
Eckert, S1
Lundershausen, R1
Scherbaum, WA1
Schnell, O1
Standl, E1
Schumm-Draeger, PM1
Walter, H1
Weber, M1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®[NCT01043029]Phase 2302 participants (Actual)Interventional2010-05-31Completed
Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571]1,080 participants (Anticipated)Observational2019-04-01Recruiting
Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia[NCT00770653]Phase 3305 participants (Actual)Interventional2007-04-30Completed
A Single-Arm, Open-Label, Multicenter Study Evaluating the Triglyceride Changes in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia Following Treatment Conversion From Rosiglitazone to Pioglitazone HCl in Combination With Stable Statin Therapy[NCT00672919]Phase 4305 participants (Actual)Interventional2003-11-30Completed
Pioglitazone Versus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia[NCT00331487]Phase 3719 participants (Actual)Interventional2000-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Adiponectin.

The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionμg/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID6.79
Glimepiride 2 mg and Metformin 850 mg BID0.72

Change From Baseline in Diastolic Blood Pressure.

The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

InterventionmmHg (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-1.3
Glimepiride 2 mg and Metformin 850 mg BID-0.1

Change From Baseline in E-Selectin.

The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionng/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-3.7
Glimepiride 2 mg and Metformin 850 mg BID-0.5

Change From Baseline in Erythrocyte Deformability (0.30%).

The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID1.3
Glimepiride 2 mg and Metformin 850 mg BID-0.4

Change From Baseline in Erythrocyte Deformability (0.60%)

The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID2.4
Glimepiride 2 mg and Metformin 850 mg BID-0.5

Change From Baseline in Erythrocyte Deformability (1.20).

The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.2
Glimepiride 2 mg and Metformin 850 mg BID-1.1

Change From Baseline in Erythrocyte Deformability (12.00).

The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID2.7
Glimepiride 2 mg and Metformin 850 mg BID-1.3

Change From Baseline in Erythrocyte Deformability (3.00).

The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.3
Glimepiride 2 mg and Metformin 850 mg BID-.15

Change From Baseline in Erythrocyte Deformability (30.00).

The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID2.5
Glimepiride 2 mg and Metformin 850 mg BID-1.3

Change From Baseline in Erythrocyte Deformability (6.00).

The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.1
Glimepiride 2 mg and Metformin 850 mg BID-1.4

Change From Baseline in Erythrocyte Deformability (60.00).

The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID2.7
Glimepiride 2 mg and Metformin 850 mg BID-1.3

Change From Baseline in Fasting Glucose.

The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-21.6
Glimepiride 2 mg and Metformin 850 mg BID-21.1

Change From Baseline in Fasting Intact Proinsulin.

The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpmol/L (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-5.18
Glimepiride 2 mg and Metformin 850 mg BID-0.11

Change From Baseline in Glycosylated Hemoglobin.

The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-0.83
Glimepiride 2 mg and Metformin 850 mg BID-0.95

Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).

The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/L (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-0.87
Glimepiride 2 mg and Metformin 850 mg BID0.00

Change From Baseline in High Sensitivity C-reactive Protein (Original).

The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/L (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-0.21
Glimepiride 2 mg and Metformin 850 mg BID-0.04

Change From Baseline in High-Density Lipoprotein Cholesterol.

The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.3
Glimepiride 2 mg and Metformin 850 mg BID-0.4

Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.

The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID0.1
Glimepiride 2 mg and Metformin 850 mg BID0.3

Change From Baseline in Low-Density Lipoprotein Cholesterol.

The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID9.7
Glimepiride 2 mg and Metformin 850 mg BID11.2

Change From Baseline in Low-Density Lipoprotein Subfractions.

The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID6.2
Glimepiride 2 mg and Metformin 850 mg BID6.1

Change From Baseline in Matrix Metallo Proteinase-9.

The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionng/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID31.4
Glimepiride 2 mg and Metformin 850 mg BID51.6

Change From Baseline in Nitrotyrosine.

The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionnmol/L (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-2.7
Glimepiride 2 mg and Metformin 850 mg BID32.5

Change From Baseline in Platelet Function.

The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionsec (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-30.3
Glimepiride 2 mg and Metformin 850 mg BID-1.0

Change From Baseline in Soluble CD40 Ligand.

The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpg/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-40.7
Glimepiride 2 mg and Metformin 850 mg BID102.4

Change From Baseline in Soluble Intracellular Adhesion Molecule.

The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionng/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-13.0
Glimepiride 2 mg and Metformin 850 mg BID-3.2

Change From Baseline in Soluble Vascular Cell Adhesion Molecule.

The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionng/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID11.6
Glimepiride 2 mg and Metformin 850 mg BID3.3

Change From Baseline in Systolic Blood Pressure.

The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

InterventionmmHg (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-2.5
Glimepiride 2 mg and Metformin 850 mg BID0.5

Change From Baseline in Thromboxane B2.

The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpg/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-216.4
Glimepiride 2 mg and Metformin 850 mg BID527.8

Change From Baseline in Triglycerides.

The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-40.9
Glimepiride 2 mg and Metformin 850 mg BID-16.7

Change From Baseline in Von-Willebrand Factor.

The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-19.5
Glimepiride 2 mg and Metformin 850 mg BID1.4

Intake of Study Medication Greater Than 80% and Less Than 120%.

The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionparticipants (Number)
Pioglitazone 15 mg and Metformin 850 mg BID136
Glimepiride 2 mg and Metformin 850 mg BID137

The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.

The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.2
Glimepiride 2 mg and Metformin 850 mg BID-0.3

Reviews

11 reviews available for pioglitazone and Dyslipidemias

ArticleYear
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
    Current cardiology reports, 2017, Volume: 19, Issue:7

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Glucagon-Like Peptid

2017
Pathophysiology of Diabetic Dyslipidemia.
    Journal of atherosclerosis and thrombosis, 2018, Sep-01, Volume: 25, Issue:9

    Topics: Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chylomicrons; Diabetes

2018
Gender-specific risk factors for gout: a systematic review of cohort studies.
    Advances in rheumatology (London, England), 2019, 06-24, Volume: 59, Issue:1

    Topics: Age Factors; Animals; Body Size; Body Weight; Cohort Studies; Diabetes Complications; Diet; Diuretic

2019
Nonalcoholic fatty liver disease: new treatments.
    Current opinion in gastroenterology, 2015, Volume: 31, Issue:3

    Topics: Antioxidants; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Insulin Resistanc

2015
Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.
    Current clinical pharmacology, 2008, Volume: 3, Issue:2

    Topics: Adipose Tissue; Apolipoproteins; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Humans; Hy

2008
The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?
    Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:13

    Topics: Biomarkers; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypoglycemic Agents; Lipoproteins, HDL

2008
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:1

    Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type

2009
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
    Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:11

    Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; H

2010
Pioglitazone: a review of its use in type 2 diabetes mellitus.
    Drugs, 2006, Volume: 66, Issue:1

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drug T

2006
The metabolic basis of atherogenic dyslipidemia.
    Clinical cornerstone, 2005, Volume: 7, Issue:2-3

    Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; D

2005
[Therapy with glitazones--a risk for cardiovascular disease?].
    Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:49

    Topics: Cardiovascular Diseases; Cholesterol, LDL; Contraindications; Diabetes Mellitus, Type 2; Dyslipidemi

2007

Trials

16 trials available for pioglitazone and Dyslipidemias

ArticleYear
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
    Cardiovascular diabetology, 2020, 06-19, Volume: 19, Issue:1

    Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method;

2020
Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
    The Journal of clinical endocrinology and metabolism, 2017, 08-01, Volume: 102, Issue:8

    Topics: Alanine Transaminase; Aspartate Aminotransferases; Cardiovascular Diseases; Diabetes Mellitus, Type

2017
Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia.
    JPMA. The Journal of the Pakistan Medical Association, 2017, Volume: 67, Issue:12

    Topics: Adult; Aged; Body Mass Index; Body Weight; Dyslipidemias; Female; Gemfibrozil; Humans; Hypoglycemic

2017
Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
    Alimentary pharmacology & therapeutics, 2019, Volume: 49, Issue:9

    Topics: Adult; Biomarkers; Biopsy; Dyslipidemias; E-Selectin; Female; Humans; Intercellular Adhesion Molecul

2019
Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue.
    Endocrine, 2014, Volume: 45, Issue:3

    Topics: 3T3-L1 Cells; Adipocytes; Adult; Animals; Disease Models, Animal; Dyslipidemias; Fenofibrate; Humans

2014
Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study.
    Journal of atherosclerosis and thrombosis, 2014, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipid

2014
No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
    The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:10

    Topics: Aged; Animals; Aorta; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascu

2014
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
    BMC nephrology, 2014, Nov-18, Volume: 15

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female;

2014
Withdrawal of pioglitazone in patients with type 2 diabetes mellitus.
    Journal of clinical pharmacy and therapeutics, 2010, Volume: 35, Issue:4

    Topics: Adiponectin; Alkaline Phosphatase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Sch

2010
[Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69, Issue:1

    Topics: Aged; Arteriosclerosis; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Ty

2011
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Diabetes technology & therapeutics, 2011, Volume: 13, Issue:6

    Topics: Adiponectin; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL;

2011
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Diabetologia, 2005, Volume: 48, Issue:12

    Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2;

2005
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.
    Diabetes & vascular disease research, 2006, Volume: 3, Issue:1

    Topics: Adolescent; Adult; Aged; Apolipoproteins; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholest

2006
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
    Diabetes care, 2007, Volume: 30, Issue:10

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Fatty Acids, Nonesterified; Glycated

2007
The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Metabolism: clinical and experimental, 2007, Volume: 56, Issue:9

    Topics: Adult; Alkanesulfonates; Anticholesteremic Agents; Atorvastatin; Chemotherapy, Adjuvant; Cross-Over

2007
The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2008, Volume: 18, Issue:5

    Topics: Aged; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dru

2008

Other Studies

16 other studies available for pioglitazone and Dyslipidemias

ArticleYear
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
    Journal of medicinal chemistry, 2009, Jul-23, Volume: 52, Issue:14

    Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2;

2009
Modulation of Insulin Resistance, Dyslipidemia and Serum Metabolome in iNOS Knockout Mice following Treatment with Nitrite, Metformin, Pioglitazone, and a Combination of Ampicillin and Neomycin.
    International journal of molecular sciences, 2021, Dec-24, Volume: 23, Issue:1

    Topics: Ampicillin; Animals; Drug Therapy, Combination; Dyslipidemias; Glucose; Homeostasis; Hypoglycemic Ag

2021
Diabetes as First Manifestation of Autoimmune Pancreatitis.
    The American journal of the medical sciences, 2017, Volume: 353, Issue:5

    Topics: Adrenal Cortex Hormones; Aged; Autoimmune Diseases; Diabetes Complications; Diabetes Mellitus; Dysli

2017
Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors.
    Chemico-biological interactions, 2019, Jan-05, Volume: 297

    Topics: Animals; Diet; Dyslipidemias; Inflammation; Male; Pioglitazone; Polycyclic Sesquiterpenes; PPAR alph

2019
Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats.
    Environmental toxicology and pharmacology, 2019, Volume: 66

    Topics: Animals; Aorta, Thoracic; Blood Glucose; Body Weight; C-Reactive Protein; Dyslipidemias; Fatty Liver

2019
Non-glycemic effects of pioglitazone and incretin-based therapies.
    Expert opinion on therapeutic targets, 2013, Volume: 17, Issue:7

    Topics: Body Weight; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Incretins; Pioglit

2013
Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome.
    The Annals of pharmacotherapy, 2014, Volume: 48, Issue:1

    Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Drug Resistance; Drug

2014
Hyperinsulinaemic androgen excess in adolescent girls.
    Nature reviews. Endocrinology, 2014, Volume: 10, Issue:8

    Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human

2014
A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor γ with Excellent Effect on Insulin Resistance and Type 2 Diabetes.
    The Journal of pharmacology and experimental therapeutics, 2015, Volume: 353, Issue:3

    Topics: 3-Mercaptopropionic Acid; Animals; Blood Glucose; Cell Line; Cell Survival; Diabetes Mellitus, Exper

2015
Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
    Current medical research and opinion, 2008, Volume: 24, Issue:11

    Topics: Aged; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Dise

2008
Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone.
    Circulation, 2011, Jul-05, Volume: 124, Issue:1

    Topics: Animals; Blood Vessels; Disease Models, Animal; Disease Progression; Dyslipidemias; Hyperinsulinism;

2011
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
    Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:9

    Topics: Animals; Apolipoprotein E2; Apolipoproteins E; Atherosclerosis; Blood Glucose; Disease Models, Anima

2005
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice.
    Proceedings of the National Academy of Sciences of the United States of America, 2006, Mar-07, Volume: 103, Issue:10

    Topics: Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; AT

2006
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
    British journal of pharmacology, 2006, Volume: 148, Issue:5

    Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expr

2006
Case report of Klinefelter's syndrome with severe diabetes, dyslipidemia, and stroke: The effect of pioglitazone and other anti-inflammatory agents on interleukin-6 and -8, tumor necrosis factor-alpha, and C-reactive protein.
    Diabetes care, 2006, Volume: 29, Issue:8

    Topics: Adult; Anti-Inflammatory Agents; C-Reactive Protein; Diabetes Mellitus; Dyslipidemias; Humans; Inter

2006
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
    Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:49

    Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycate

2007